Medicamen Biotech Limited has issued an official clarification regarding an incorrect event display appearing on the National Securities Depository Limited (NSDL) portal under the company's login credentials. The pharmaceutical company emphasized that no such event has been initiated, authorized, or undertaken by the organization.

Clarification Details

In a regulatory filing dated April 6, 2026, the company addressed the inadvertent display on the NSDL portal. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Response

Medicamen Biotech has taken immediate action to address the situation. The company has already escalated the matter with NSDL for necessary verification and rectification of the incorrect display. Management confirmed that there is no material event or information requiring disclosure from the company's end regarding this matter.

Corporate Information

The clarification was signed by Company Secretary Parul Choudhary (ACS: 44157) on behalf of Medicamen Biotech Limited. The company maintains its registered and corporate office at Chiranjiv Tower, Nehru Place, New Delhi, and operates under CIN L74899DL1993PLC056594.

Regulatory Compliance

This disclosure demonstrates the company's commitment to maintaining transparency with stakeholders and ensuring accurate information dissemination. The proactive clarification helps prevent any potential confusion among investors and market participants regarding the company's actual corporate activities and events.

Medicamen Biotech Limited has disclosed receiving a cautionary letter from the National Stock Exchange of India Limited regarding observations in its Secretarial Compliance Report. The company made this disclosure on February 21, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Communication Details

The company received the cautionary letter via email from NSE on January 27, 2026. The communication pertained to observations reported by the Secretarial Auditor in the Annual Secretarial Compliance Report submitted for the financial year ended March 31, 2025.

Nature of Observations

According to the disclosure, the Secretarial Auditor had reported certain observations in the Annual Secretarial Compliance Report. While specific details of the violations or contraventions were not elaborated, NSE advised the company to exercise greater caution in future operations.

The exchange specifically recommended that Medicamen Biotech:

• Avoid recurrence of such lapses in compliance
• Adhere strictly to requirements of applicable provisions and regulations
• Ensure compliance with Listing Regulations going forward

Business Impact Assessment

The company has explicitly stated that the cautionary letter has no impact on its financial position, operations, or other business activities. This disclosure was made in compliance with Schedule III of the Listing Regulations and SEBI Master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Regulatory Compliance Framework

The disclosure was signed by Parul Choudhary, Company Secretary (ACS: 44157), and submitted to both BSE Limited and National Stock Exchange of India Limited. The company maintains its commitment to regulatory compliance and has acknowledged the need for enhanced adherence to listing obligations in future reporting periods.